Monoclonal antibody directed against CXCR5
US9534054B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2014 |
| Grant date | Jan 3, 2017 |
| Priority date | — |
| Expiry date | Apr 30, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.